X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
1. Daranide
2. Dichlofenamide
3. Diclofenamid
4. Glauconide
1. Diclofenamide
2. 120-97-8
3. 4,5-dichlorobenzene-1,3-disulfonamide
4. Dichlofenamide
5. Dichlorophenamide
6. Daranide
7. Antidrasi
8. Dichlorphenamid
9. Glauconide
10. Glaucol
11. Oratrol
12. 1,3-benzenedisulfonamide, 4,5-dichloro-
13. 4,5-dichloro-m-benzenedisulfonamide
14. Diclofenamida
15. Diclofenamidum
16. 1,3-disulfamyl-4,5-dichlorobenzene
17. Diclofenamidum [inn-latin]
18. 1,3-disulfamoyl-4,5-dichlorobenzene
19. 4,5-dichloro-1,3-disulfamoylbenzene
20. Diclofenamida [inn-spanish]
21. 3,4-dichloro-5-sulfamylbenzenesulfonamide
22. Keveyis
23. 4,5-dichloro-1,3-benzenedisulfonamide
24. Cb 8000
25. M-benzenedisulfonamide, 4,5-dichloro-
26. Diclofenamide [inn]
27. Dichlorphenamide (usp)
28. Dichlorphenamide [usp]
29. Chembl17
30. Diclofenamid
31. Vvj6673mhy
32. Barastonin
33. Dichlorphenamide (diclofenamide)
34. Glajust
35. Glaumid
36. Glafco
37. Chebi:101085
38. 4,5-dichloro-benzene-1,3-disulfonic Acid Diamide
39. Ncgc00016371-01
40. Cas-120-97-8
41. Dasanide
42. Daranide (tn)
43. Hsdb 3267
44. 120d978
45. Dichlorophenamide (dcp)
46. Einecs 204-440-6
47. Unii-vvj6673mhy
48. Brn 2703329
49. Diclorfenamida
50. Diclorfenammide
51. Sulfonamide 4
52. 2pou
53. 4,5-dichloro-m-benzendisulfonamide
54. Keveyis (tn)
55. Prestwick_1071
56. Dichlorophenamide, Dcp
57. Prestwick0_000809
58. Prestwick1_000809
59. Prestwick2_000809
60. Prestwick3_000809
61. Diclofenamide (jan/inn)
62. Dsstox_cid_2922
63. Diclofenamide [jan]
64. Dsstox_rid_76789
65. Dsstox_gsid_22922
66. Bspbio_000677
67. Dichlorphenamide [mi]
68. Mls002154010
69. Diclofenamide [mart.]
70. Schembl112376
71. Spbio_002598
72. Dichlorphenamide [hsdb]
73. Diclofenamide [who-dd]
74. Bpbio1_000745
75. Gtpl6807
76. Dtxsid1022922
77. Bdbm10883
78. Amy7513
79. Dichlorphenamide [usp-rs]
80. Hms1570b19
81. Hms2097b19
82. Hms2236i07
83. Hms3373g04
84. Hms3655h06
85. Hms3714b19
86. Hms3745k19
87. Zinc896918
88. Bcp22591
89. Ex-a1311
90. Hy-b0397
91. Tox21_110401
92. Mfcd00148948
93. S2177
94. 4,5-dichlorobenzene1,3-disulfonamide
95. Dichlorphenamide [orange Book]
96. Akos015899860
97. Ccg-220809
98. Db01144
99. Dichlorphenamide [usp Impurity]
100. 4,5-dicholorobenzene-1,3-disulfonamide
101. Dichlorphenamide [usp Monograph]
102. Ncgc00016371-02
103. Ncgc00016371-04
104. Ncgc00016371-05
105. Ncgc00016371-06
106. Ncgc00016371-08
107. Ac-25007
108. As-63955
109. I7a
110. Smr001233338
111. 4,5-dichloro-1,3-benzenedisulfonamide #
112. Ft-0648264
113. Sw197138-3
114. A21072
115. C07459
116. D00518
117. Sr-01000841825
118. Q3706987
119. Sr-01000841825-2
120. W-108466
121. Brd-k71499074-001-03-8
122. Dichlorphenamide, United States Pharmacopeia (usp) Reference Standard
123. Diclofenamide; Dichlofenamide; Daranide; 4,5-dichlorobenzene-1,3-disulfonamide
| Molecular Weight | 305.2 g/mol |
|---|---|
| Molecular Formula | C6H6Cl2N2O4S2 |
| XLogP3 | 0.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 303.9146044 g/mol |
| Monoisotopic Mass | 303.9146044 g/mol |
| Topological Polar Surface Area | 137 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 452 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Carbonic Anhydrase Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
...USED IN TREATMENT OF PRIMARY GLAUCOMA, ACUTE PHASE OF SECONDARY GLAUCOMA, & IN PREOPERATIVE CONTROL OF INTRAOCULAR TENSION. ... ALTHOUGH IT HAS DIURETIC PROPERTIES, IT IS NOT PROMOTED FOR THIS PURPOSE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 866
...DRUG HAS BEEN FOUND TO INHIBIT EPILEPTIC SEIZURES & TO DECR RATE OF SPINAL FLUID FORMATION. /ACETAZOLAMIDE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 827
...REDUCES RATE OF AQ HUMOR FORMATION; INTRAOCULAR PRESSURE IN PT WITH GLAUCOMA IS CORRESPONDINGLY REDUCED. THIS ACTION OF DRUG APPEARS TO BE INDEPENDENT OF SYSTEMIC ACID-BASE BALANCE. /ACETAZOLAMIDE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 827
For more Therapeutic Uses (Complete) data for DICHLORPHENAMIDE (11 total), please visit the HSDB record page.
IT HAS BEEN SUGGESTED THAT POSTOPERATIVE USE /AFTER IRIDECTOMY/...MAY ADVERSELY AFFECT OUTCOME OF FILTERING OPERATIONS BY REDUCING SIZE OF RESULTANT DRAINAGE BLEB & DELAYING REFORMATION OF ANTERIOR CHAMBER. /CARBONIC ANHYDRASE INHIBITORS/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 933
...SHOULD BE USED CAUTIOUSLY IN PT WITH OBSTRUCTIVE PULMONARY DISEASE BECAUSE THEY MAY PPT ACUTE RESPIRATORY FAILURE. /CARBONIC ANHYDRASE INHIBITORS/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 933
DIURESIS MAY BE TROUBLESOME INITIALLY BUT SUBSIDES DURING CONTINUED THERAPY BECAUSE OF PERSISTENT METABOLIC ACIDOSIS. /CARBONIC ANHYDRASE INHIBITORS/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 932
...BE GIVEN CAUTIOUSLY TO PT...WITH DISEASES ASSOC WITH INCR MINERALOCORTICOID ACTIVITY (EG, PRIMARY HYPERALDOSTERONISM, CUSHING'S SYNDROME) & THOSE RECEIVING POTASSIUM-WASTING DRUGS (EG, THIAZIDES, LOOP DIURETICS, CORTICOSTEROIDS). /CARBONIC ANHYDRASE INHIBITORS/
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 933
For more Drug Warnings (Complete) data for DICHLORPHENAMIDE (7 total), please visit the HSDB record page.
For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
Dichlorphenamide is an oral carbonic anhydrase inhibitor indicated for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow).
Carbonic Anhydrase Inhibitors
A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EC - Carbonic anhydrase inhibitors
S01EC02 - Diclofenamide
Carbonic anhydrase inhibitors reduce intraocular pressure by partially suppressing the secretion of aqueous humor (inflow), although the mechanism by which they do this is not fully understood. Evidence suggests that HCO3- ions are produced in the ciliary body by hydration of carbon dioxide under the influence of carbonic anhydrase and diffuse into the posterior chamber which contains more Na+ and HCO3- ions than does plasma and consequently is hypertonic. Water is then attracted to the posterior chamber by osmosis, resulting in a drop in pressure.
PHOSPHATURIA MAY BE RELATED TO DIRECT STIMULATION...OF CYCLIC ADENOSINE 3',5'-MONOPHOSPHATE...PRODN BY KIDNEY. ...DRUG ACTS SIMILARLY TO PARATHYROID HORMONE IN ENHANCING URINARY EXCRETION OF PHOSPHATE & CYCLIC AMP, IN CONTRAST TO ITS ANTAGONISM OF ACTION OF HORMONE ON BONE. /ACETAZOLAMIDE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826
...INHIBITION OF...CARBONIC ANHYDRASE. ...IS NONCOMPETITIVE. ...ENZYME IS NORMALLY PRESENT IN TISSUES IN HUGE EXCESS. MORE THAN 99% OF ENZYME ACTIVITY IN KIDNEY MUST BE INHIBITED BEFORE PHYSIOLOGICAL EFFECTS BECOME APPARENT. ENZYME...IS DOMINANT TISSUE COMPONENT TO WHICH INHIBITORS BECOME BOUND. /ACETAZOLAMIDE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826
/CHANGES IN URINE/...MAY BE ATTRIBUTED TO INHIBITION OF (+)H SECRETION BY RENAL TUBULE. ... CURRENT EVIDENCE INDICATES GREATER EFFECT ON PROXIMAL THAN ON DISTAL TUBULE, WITH LITTLE OR NO EFFECT ON ASCENDING LIMB. ...PHOSPHATURIA...USED AS INDEX OF LOCALIZING DIURETIC ACTION... /ACETAZOLAMIDE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826
...INCR URINARY EXCRETION OF BICARBONATE & FIXED CATION, MOSTLY SODIUM. AS RESULT, CONCN OF BICARBONATE IN EXTRACELLULAR FLUID DECR & METABOLIC ACIDOSIS RESULTS. ...RENAL RESPONSE TO ACETAZOLAMIDE IS GREATLY REDUCED.../BUT/ DIURETIC RESPONSE IS ENHANCED. /ACETAZOLAMIDE/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 826
DRUG LOWERS INTRAOCULAR PRESSURE BY REDUCING RATE OF SECRETION OF AQ HUMOR.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 867
Market Place
